TORONTO, Jan. 8, 2025
/CNW/ - AmacaThera, a leading clinical-stage biotechnology company
revolutionizing long-acting therapies, announces the appointment of
Dr. Eyal S. Ron to its Board of
Directors. A seasoned entrepreneur and life sciences strategist,
Dr. Ron brings over three decades of experience in developing and
scaling groundbreaking healthcare solutions, corporate strategic
growth, and patient-focused solutions. His expertise will guide
AmacaThera as it advances both clinical pipeline products and
strategic global partnerships.
"Joining AmacaThera's Board at this pivotal moment is a great
honour," said Dr. Ron. "Having collaborated closely with the
management team for some time, I am excited to contribute more
actively as the Company advances into Phase 2 clinical trials for
AMT-143 in post-operative pain. I am also eager to support the
development of additional innovative therapies derived from the
proprietary AmacaGel™ platform. This hydrogel technology has
significant potential to overcome delivery challenges in the
pharmaceutical industry across a range of indications and
modalities."
"Dr. Ron combines unmatched scientific expertise combined with a
track record of effective business leadership, making him a key
driver of innovation and growth at AmacaThera." said Dr.
Mike Cooke, CEO of AmacaThera. "His
exceptional ability to foster innovation, establish strategic
partnerships, lead business development initiatives, and provide
strong governance will be instrumental in advancing the Company's
strategic goals and accelerating the development of groundbreaking
therapies. His appointment reinforces AmacaThera's commitment
to scaling its transformative platform technology, AmacaGel™, to
meet the needs of patients globally."
About AmacaThera
AmacaThera is a clinical-stage biotechnology company focused on
advanced sustained-release hydrogel formulations designed to
address critical challenges in therapeutic drug delivery. The
Company's flagship platform, AmacaGel™, enables the
development of long-acting therapies that enhance patient outcomes
while minimizing systemic side effects. AmacaThera is driving
innovation in key therapeutic areas, including pain management and
oncology.
The Company's lead product, AMT-143, is currently advancing into
Phase 2 clinical trials. It has demonstrated best-in-class
pharmacokinetics, showing strong potential to as an alternative to
opioid-based solutions in post-operative pain management.
AmacaThera's proprietary AmacaGel™ platform is a fast-gelling
physical hydrogel composed of two well-established polymers.
Designed to liquefy under shear force, AmacaGel can be delivered
via a conventional syringe and rapidly forms a depot as it warms to
body temperature. The platform's lead asset, AMT-143, is a
slow-release, non-opioid local anesthetic that leverages the
AmacaGel technology to provide long-acting post-operative pain
relief.
AmacaThera is backed by prominent investors, including Lumira
Ventures, BDC Capital, StandUp Ventures, MaRS IAF, and Changrong
Capital.
About Dr. Eyal S. Ron
Dr. Eyal S. Ron has a proven
track record of elevating biotech startups and steering them toward
successful exits while delivering impactful solutions to patients
and stakeholders. He played a critical role in developing
cutting-edge products, including sustained-release oral dosage
forms (Perfusia® and Plenity™), implantable
biodegradable sustained-release devices (Gliadel®,
Nutropin Depot®, InFuse®, and
ProLease®), and biodegradable sealants
(FocalSeal®). Dr. Ron has driven numerous companies to
success, achieving exits valued at over $1
billion.
For more information, visit www.amacathera.ca.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/dr-eyal-s-ron-joins-amacathera-board-of-directors-to-drive-strategic-growth-and-accelerate-innovation-in-long-acting-therapies-302345083.html
SOURCE AmacaThera Inc.
